Lord Abbett & CO. LLC Purchases 66,183 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Lord Abbett & CO. LLC raised its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 26.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 312,425 shares of the company’s stock after acquiring an additional 66,183 shares during the period. Lord Abbett & CO. LLC’s holdings in Vaxcyte were worth $35,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vaxcyte by 68.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after buying an additional 8,685 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Vaxcyte by 61.1% during the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares during the last quarter. Tri Locum Partners LP purchased a new position in Vaxcyte during the second quarter worth $8,559,000. Hsbc Holdings PLC purchased a new stake in shares of Vaxcyte in the second quarter valued at $1,053,000. Finally, Lisanti Capital Growth LLC boosted its stake in shares of Vaxcyte by 68.1% during the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock worth $3,715,000 after purchasing an additional 13,175 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Trading Down 0.2 %

Shares of NASDAQ:PCVX opened at $87.72 on Friday. The company has a market capitalization of $10.93 billion, a PE ratio of -19.07 and a beta of 0.94. Vaxcyte, Inc. has a 12-month low of $53.83 and a 12-month high of $121.06. The business has a 50 day moving average of $101.11 and a two-hundred day moving average of $91.68.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the business posted ($0.91) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

PCVX has been the subject of several analyst reports. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Bank of America increased their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Jefferies Financial Group upped their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Leerink Partners increased their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $147.50.

Insider Buying and Selling

In other news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The trade was a 8.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $91.49, for a total transaction of $457,450.00. Following the completion of the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at $2,625,488.53. This represents a 14.84 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,830 shares of company stock valued at $12,600,310. 3.10% of the stock is owned by corporate insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.